Johnson & Johnson's Getting Back to Double-Digit Growth. Has the Stock Become a Bargain Buy?

Johnson & Johnson (NYSE: JNJ) is 1 of the largest healthcare companies successful the world. But it hasn't ever been a terribly breathtaking concern to put in. While it has been growing, it's typically been astatine a humble pace. The main crushed for investing successful the banal has been its dividend.

The company, however, has been investing successful its pipeline successful the hopes of achieving amended maturation successful the future. And that looks to beryllium paying off, arsenic the institution precocious unveiled promising guidance for the twelvemonth ahead. Could Johnson & Johnson banal beryllium a imaginable bargain bargain successful 2026?

Where to put $1,000 close now? Our expert squad conscionable revealed what they judge are the 10 champion stocks to bargain close now, erstwhile you articulation Stock Advisor. See the stocks »

Last month, Johnson & Johnson reported its full-year results for 2025. It was different coagulated twelvemonth for the business, with gross climbing by 6% to $94.2 billion. That's successful enactment with what investors person travel to expect from the concern successful caller years. In 2024, its apical enactment roseate by a much humble complaint of 4%, but for the ample part, single-digit maturation has been the norm for Johnson & Johnson.

Business, however, is trending higher. The company's CEO, Joaquin Duato, believes that much maturation is connected the horizon, saying, "We person enactment of show to double-digit maturation by the extremity of the decade."

A large portion of the crushed for this maturation is oncology, arsenic Johnson & Johnson wants to beryllium the starring crab drugmaker successful the world. It's hoping to bring successful $50 cardinal from its oncology business, which is astir treble what it generated this past year.

For 2026, Johnson & Johnson absorption projects gross of $100.5 billion, implying a maturation complaint of astir 6.7%. Its apical enactment is showing immoderate encouraging signs of progress, perchance making this an charismatic enactment for maturation investors successful the future.

Currently, the banal trades astatine astir 21 times its trailing earnings. And based connected its expected maturation implicit the adjacent 5 years, its price-to-earnings-growth (PEG) aggregate is astir 1.2. That's supra the 1.0 cutoff that investors look for successful the PEG ratio to signify that a banal is simply a bargain buy.

While it whitethorn not beryllium a bargain of a deal, with the concern connected the cusp of immoderate breathtaking growth, Johnson & Johnson's banal could beryllium to beryllium a bully semipermanent buy. It's already seen arsenic a safe-haven benignant of banal to own, arsenic it pays a coagulated dividend that yields 2.3%. Adding much maturation to the premix could assistance it soar higher successful the years ahead.